Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sivakumar Munnangi

Gastroenterology Merced, CA Medical Doctor

NPI 1447432463 CMS profile 246831

386 W Olive Ave, Suite A, Merced, CA 95348

Open in the dashboard

General payments

$8,700

561 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sivakumar Munnangi of Merced, CA is reported in the CMS Open Payments database as having received $8,700 across 561 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,640 77
2024 General $1,502 69
2023 General $1,353 72
2022 General $1,260 96
2021 General $1,080 78
2020 General $829 68
2019 General $1,035 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sivakumar Munnangi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Sivakumar Munnangi were reported at $1,640. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Sivakumar Munnangi Gastroenterology median Middle half National median
2019 $1,035 $417 $126–$1,100 $163
2020 $829 $224 $74–$624 $114
2021 $1,080 $352 $106–$1,054 $132
2022 $1,260 $448 $129–$1,270 $149
2023 $1,353 $533 $150–$1,390 $160
2024 $1,502 $605 $160–$1,606 $164
2025 $1,640 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,542 148 payments
  2. Gilead Sciences, Inc. $2,326 158 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,355 115 payments
  4. Janssen Biotech, Inc. $559 24 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $345 22 payments
  6. Ardelyx, Inc. $278 18 payments
  7. Braintree Laboratories, Inc. $191 8 payments
  8. Celgene Corporation $186 15 payments
  9. Intercept Pharmaceuticals, Inc. $175 12 payments
  10. Pfizer Inc. $119 7 payments
  11. Other $624 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,601 560 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,300 112 payments
  2. MAVYRET $1,185 57 payments
  3. LINZESS $459 30 payments
  4. CREON $426 28 payments
  5. RINVOQ $384 24 payments
  6. TREMFYA $371 15 payments
  7. HUMIRA $293 23 payments
  8. STELARA $280 13 payments
  9. IBSRELA $278 18 payments
  10. ENTYVIO $274 14 payments
  11. Other $2,362 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,378

Median for Gastroenterology: 569

Drug cost

$238,367

Median for Gastroenterology: $104,976

Branded share of claims

61.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 20 $64,297
Linzess Linaclotide Brand 38 $46,214
Vemlidy Tenofovir Alafenamide Brand 29 $43,693
Viberzi Eluxadoline Brand 11 $17,964
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 183 $11,703
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 508 $8,004
Mesalamine Generic 25 $5,630
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 282 $5,034
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 30 $4,834
Omeprazole Generic 335 $3,778

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$282,985

Medicare's payments for the services billed

Medicare patients

1,444

Average age 71

Services billed

2,907

835 women, 609 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 40%
Ischemic heart disease 28%
Chronic kidney disease 23%
Heart failure 18%
COPD 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MAVYRET
  • AbbVie, Inc. $187
$187 — —
Epclusa
  • Gilead Sciences, Inc. $186
$186 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $146
$146 20 —
STELARA
  • Janssen Biotech, Inc. $128
$128 — —
RINVOQ
  • AbbVie, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

561 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record